Merck KGaA MKGAF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MKGAF is a good fit for your portfolio.
News
-
Merck KGaA to Open $326 Million Pharmaceutical Plant in South Korea to Expand in Asia
-
Merck KGaA Expects Organic Sales, Earnings Growth This Year
-
Merck KGaA Supervisory Board Elects Michael Kleinemeier as Chair Until Annual Meeting
-
Merck KGaA Supervisory Board Chairman Wolfgang Buechele to Step Down
-
German stocks rise after ending at a record high
-
Trending: Merck's Multiple Sclerosis Drug Misses Expectations in Late-Stage Trials
-
Merck Shares Slump After Multiple Sclerosis Drug Fails in Late-Stage Trials
-
Merck MS Drug Fails to Meet Target of Late-Stage Trials
Trading Information
- Previous Close Price
- $158.75
- Day Range
- $155.99–155.99
- 52-Week Range
- $143.46–186.41
- Bid/Ask
- $154.10 / $156.20
- Market Cap
- $67.82 Bil
- Volume/Avg
- 90 / 910
Key Statistics
- Price/Earnings (Normalized)
- 19.13
- Price/Sales
- 3.04
- Dividend Yield (Trailing)
- 1.53%
- Dividend Yield (Forward)
- 1.51%
- Total Yield
- 1.53%
Company Profile
Merck KGaA operates in three main segments: life sciences, performance materials, and healthcare. The life sciences segment (44% of 2023 sales) primarily provides laboratory consumables and services to researchers in academia and applied fields, including the biopharmaceutical industry. In the healthcare segment (38%), Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In its electronics segment (17%), the company offers specialty materials to manufacture a variety of products, such as semiconductors, flat-screen televisions, automobiles, and cosmetics. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Large Core
- Total Number of Employees
- 62,908
- Website
- https://www.emdgroup.com
Competitors
Valuation
|
Metric
|
MKGAF
|
BIIB
|
DHR
|
|---|---|---|---|
Price/Earnings (Normalized) | 19.13 | 12.93 | 27.74 |
Price/Book Value | 2.34 | 1.87 | 3.27 |
Price/Sales | 3.04 | 2.82 | 7.35 |
Price/Cash Flow | 14.20 | 12.63 | 25.52 |
Price/Earnings
MKGAF
BIIB
DHR
Financial Strength
|
Metric
|
MKGAF
|
BIIB
|
DHR
|
|---|---|---|---|
Quick Ratio | 0.79 | 0.92 | 1.18 |
Current Ratio | 1.42 | 2.00 | 1.68 |
Interest Coverage | 11.32 | 5.13 | 17.58 |
Quick Ratio
MKGAF
BIIB
DHR
Profitability
|
Metric
|
MKGAF
|
BIIB
|
DHR
|
|---|---|---|---|
Return on Assets (Normalized) | 7.55% | 8.29% | 5.68% |
Return on Equity (Normalized) | 13.81% | 15.11% | 9.47% |
Return on Invested Capital (Normalized) | 10.19% | 10.01% | 6.69% |
Return on Assets
MKGAF
BIIB
DHR
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Szntmbxyb | Fbcgk | $70.0 Bil | |
MKKGY
| Merck KGaA ADR | Zbgzjxyzd | Hlmgl | $68.1 Bil | |
HLN
| Haleon PLC ADR | Tydlxfsc | Wwqbd | $36.5 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Brlhflk | Zfnh | $14.3 Bil | |
VTRS
| Viatris Inc | Rrpjzwjd | Plt | $13.2 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Qlskdkvsf | Cdsv | $12.0 Bil | |
CTLT
| Catalent Inc | Cjppljsq | Ktnydp | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Lnfyttlmt | Scfx | $4.1 Bil | |
CURLF
| Curaleaf Holdings Inc | Bvlsrkqm | Mlpm | $3.7 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Fztdzbs | Nzkpgn | $3.4 Bil |